Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CINEOLE CRS (180 µL)

CINEOLE CRS (180 µL)

470-82-6

DISCOVER
ERYTHRITOL CRS (1020 MG)

ERYTHRITOL CRS (1020 MG)

149-32-6

DISCOVER
Proguanil hydrochloride - reference spectrum, Qty : n/a

Proguanil hydrochloride - reference spectrum, Qty : n/a

NA

DISCOVER
RIFABUTIN IMPURITY A CRS (20 MG)

RIFABUTIN IMPURITY A CRS (20 MG)

NA

DISCOVER
SQUALANE CRS (300 µL)

SQUALANE CRS (300 µL)

111-01-3

DISCOVER
HYDROXYPROPYLBETADEX CRS (200MG)

HYDROXYPROPYLBETADEX CRS (200MG)

128446-35-5

DISCOVER
RILMENIDINE FOR SYSTEM SUITABILITY CRS (30 MG)

RILMENIDINE FOR SYSTEM SUITABILITY CRS (30 MG)

85409-38-7

DISCOVER
N-METHYLPYRROLIDONE - REFERENCE SPECTRUM (N/A)

N-METHYLPYRROLIDONE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
HUMAN GLUCAGON CRS (2.94 MG)

HUMAN GLUCAGON CRS (2.94 MG)

9007-92-5

DISCOVER
CARTEOLOL HYDROCHLORIDE - REFERENCE SPECTRUM (N/A)

CARTEOLOL HYDROCHLORIDE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
CARTEOLOL FOR SYSTEM SUITABILITY CRS (30 MG)

CARTEOLOL FOR SYSTEM SUITABILITY CRS (30 MG)

51781-21-6

DISCOVER
GOSERELIN VALIDATION MIXTURE CRS (1 MG)

GOSERELIN VALIDATION MIXTURE CRS (1 MG)

NA

DISCOVER